問卷

TPIDB > Principal Investigator

Principal Investigator


CHANGHUA CHRISTIAN HOSPITAL (在職)

Division of Endocrinology

更新時間:2023-09-19

林思涵
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

23Cases

2025-07-01 - 2030-12-31

Active
A phase III, randomized, double-blind, placebo-controlled, parallel-group trial was conducted to evaluate the efficacy of AZD0780 in patients with established atherosclerotic cardiovascular disease (ASCVD) or at high risk of first ASCVD events for major adverse cardiovascular events.
  • Condition/Disease

    Patients with established atherosclerotic cardiovascular disease or at high risk of their first atherosclerotic cardiovascular event.

  • Test Drug

    AZD0780

Participate Sites
23Sites

Recruiting23Sites

2026-03-01 - 2030-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

2026-03-01 - 2030-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

2026-07-01 - 2029-12-30

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Not yet recruiting10Sites

2026-06-01 - 2028-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

2026-06-01 - 2028-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

2025-03-01 - 2030-06-30

Active
  • Condition/Disease

  • Test Drug

Participate Sites
18Sites

Recruiting18Sites

2026-07-01 - 2028-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Not yet recruiting10Sites

2021-01-01 - 2025-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2024-09-01 - 2026-05-13

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting2Sites

Terminated1Sites

1 2 3